Trial
NCT05543928
Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
OPKO Health, Inc.
Collaborators
—
Condition
Chronic Kidney Disease stage3
Intervention
CTAP101
Why stopped
FDA changed the post-marketing requirement necessitating a new study design and protocol.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-25